Johnson & Johnson
JNJ Big PharmaDiversified healthcare company with pharmaceutical, medical devices, and consumer health divisions. Key drugs include Darzalex, Stelara, and Tremfya. Recently spun off consumer health as Kenvue.
FDA Novel Drug Designations
(2017-2025)See 8 novel approvals →
Johnson & Johnson's Key Drugs
Johnson & Johnson's core commercial portfolio centers on DARZALEX, TREMFYA, ERLEADA, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
Newly diagnosed multiple myeloma in patients ineligible for autologous stem cell transplant, in combination with lenalidomide and dexamethasone
Moderate-to-severe plaque psoriasis
Metastatic Castration-Sensitive Prostate Cancer
Rheumatoid Arthritis
Schizophrenia
Johnson & Johnson News
All Johnson & Johnson news →- Nov 10, 2026 TrialsJohnson & Johnson showcases continued hematology leadership and next-generation innovation at ASH 2026 ↗
- Nov 9, 2026 TrialsJohnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer ↗
- Nov 7, 2026 TrialsJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide ↗
- Nov 7, 2026 TrialsJohnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren’s disease that reveal insights on importance of symptom improvements most valued by patients ↗
- Nov 6, 2026 TrialsNew ICOTYDE® (icotrokinra) data reinforces first-line systemic use in plaque psoriasis with powerful skin clearance and consistent safety profile ↗
Johnson & Johnson's Recent FDA Approvals
Johnson & Johnson secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Johnson & Johnson's Therapeutic Areas
Johnson & Johnson's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 14 biologic and 31 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Johnson & Johnson's Top Competitors
Johnson & Johnson's closest competitors by therapeutic-area and drug-target overlap include GSK, Sanofi, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Johnson & Johnson Pipeline Snapshot
Johnson & Johnson has 116 active clinical programs from ClinicalTrials.gov — 40 Phase 3, 22 Phase 2 and 54 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (30)
Discontinued (3)
Company Info
- First Approval
- 1945-09-12
- Latest
- 2026-09-17
- Applications
- 154
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges